Respiratory Innovation Summit

Download PDF
2 downloads 314 Views 8MB Size Report
Comment
other complications and graft failure. • Infections: leading cause of death until year 3 post-LTx. • Bronchiolitis o
pharmaceutical therapy for chronic inflammatory lung diseases

Respiratory Innovation Summit May 2018 CONFIDENTIAL ©2018 Renovion, Inc.

Lung Transplants Today

CONFIDENTIAL ©2018 Renovion, Inc.

Lung Transplant: Why are outcomes so poor? 1.

The airway is open to the environment • Constant environmental and pathogen exposure • Impaired mucociliary transport and thick mucus

2.

Environmental and pathogen exposure stimulates pathological inflammation

Essential Ions Depleted

Impaired Mucus Transport

• Chronic, low-level inflammation • Increased tissue damage and rejection

3.

Impaired mucus transport and inflammation lead to other complications and graft failure • Infections: leading cause of death until year 3 post-LTx • Bronchiolitis obliterans syndrome (BOS): leading cause of death after year 3 CONFIDENTIAL ©2018 Renovion, Inc.

Inflammation

Graft Failure

ARINA-1: Intelligent Simplicity ARINA-1 positively impacts MCT (mucus transport) and reduces inflammation to interrupt the progression to graft failure. • ARINA-1 Replaces Essential Ions

Restores Mucus Transport

• Patented therapy • Replaces ions depleted in lung transplant and other chronic inflammatory airways diseases • Nebulized directly to the airway • Administered with standard of care therapies • Lifelong maintenance therapy

Downregulates Inflammation

• Over 20 cumulative years of use in 3 patients • Decreased exacerbation rates

Maintains Graft Health

• No toxicities or adverse events

• Current Phase I Study in LTx patients at Duke University CONFIDENTIAL ©2018 Renovion, Inc.

ARINA-1: Over 20 years of patient safety and efficacy Years on Therapy

Profile

History

• CF Patient: Post-bilateral lung transplant • Late 20s at therapy initiation • ΔPhe508 homozygous

6 years

-Increased FEV1 32%, increase has been maintained -Decreased incidence of infection and rejection -No adverse events

• CF Patient: No Transplant • Late 40s at therapy initiation • ΔPhe508 homozygous

12 years

-Decreased exacerbation rate -No adverse events

• Severe Asthma Patient • Mid 50s at therapy initiation

3 years

-Decreased exacerbation rate -No adverse events

CONFIDENTIAL ©2018 Renovion, Inc.

Lung Transplant Patient: ARINA-1 increases FEV1 and decreases infections ARINA-1 Started

Multiple infections

Decreased inflammation, protection from bacterial infections

CONFIDENTIAL ©2018 Renovion, Inc.

Lung Transplant Patient: Increased mucus transport and decreased inflammation without toxicities May 9, 2012

June 5, 2012

November 18, 2013

Bronchoscopy prior to Arina-1; treatment initiated 6 days later

Post Arina-1 bronchoscopy after 21 days of treatment; same view

Follow-up approximately 18 months later

Annual bronchoscopies since May 9, 2012 have shown resolution of infection and inflammation. CONFIDENTIAL ©2018 Renovion, Inc.

1. The airway is open to the environment ARINA-1 enables the first line of immunological defense: Mucociliary Transport (MCT)

PBS

ΔMCT (mm/min)

5

Arina-1

****

PBS Arina-1

****

4

****

3 2 1 0 6

12

24

% of Total Pixels

1.5

% Area of Threshold

Time (hr)

PBS Arina-1

1.0

0.5

0.0

0

50

50

**

40 30 20 10

**P